P2RY12 and asthma: Recently, Lussana et al. published the first, randomized, double‐blind, placebo‐controlled study that pharmacologic inhibition of P2Y12 receptor may be useful in the treatment of asthma using prasugrel, a third generation P2Y12 inhibitor.